Asthma Biologics

Improving outcomes in respiratory disease is identified as a clinical priority in the NHS Long Term Plan. More than five million people in the UK have asthma with the NHS spending over £1bn per year on asthma, the vast majority of it on medication.

How We Helped

At Imperial College Health Partners we have been working with the AHSN Network, Oxford AHSN and NHS England’s AAC, to improve the Asthma pathway in NWL via Biologics therapies for patients with severe Asthma. 

Asthma biologics can have a life-changing impact on some patients with severe asthma. Biologics work in a targeted way, by disrupting pathways causing airways inflammation, helping to manage symptoms and reduce exacerbations. These therapies can transform patients’ lives by reducing long-term side effects of other treatments, such as steroids, and reduce the number of life-threatening asthma attacks.

The aims of the Biologics programme was to: 

  • Support improvements in pathways and practices to ensure more patients are able to receive specialist care for their severe asthma and access asthma biologics
  • Support up the spread and adoption of proven technological innovations and treatments which are approved by NICE but are not yet integrated into everyday practice



Our support for NWL focused on: 



Championing the Biologics Pilot Scheme in the NWL Clinical Effectiveness Group. 


Acting as the Project Management function throughout the Pilot Scheme. ​


Delivering a high-level evaluation of the Pilot Scheme to contribute to the decision to scale the Pathway. 

Explore our Biologics resources


Learn more in the Biologics toolkit

Coming soon: NWL Education Series Webinar Slides

Want to find out more about Asthma Biologics?

Back to the Asthma homepage